(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of -24.51% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 13.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.84%.
Organogenesis Holdings's revenue in 2026 is $457,454,000.On average, 4 Wall Street analysts forecast ORGO's revenue for 2026 to be $25,731,049,364, with the lowest ORGO revenue forecast at $24,148,352,423, and the highest ORGO revenue forecast at $27,102,720,045. On average, 4 Wall Street analysts forecast ORGO's revenue for 2027 to be $35,397,081,409, with the lowest ORGO revenue forecast at $30,277,121,144, and the highest ORGO revenue forecast at $40,438,550,200.
In 2028, ORGO is forecast to generate $39,505,659,727 in revenue, with the lowest revenue forecast at $32,559,807,626 and the highest revenue forecast at $46,450,225,083.